Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

3000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-02

Study Completion Date

2017-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF). Secondarily, the study monitors the results of subjective and objective findings as it applies to the non-blinded deployment of autologous SVF for various inflammatory and/or degenerative conditions including select orthopedic, neurologic, urologic and cardio-pulmonary conditions. SVF deployments include intra-venous, intra-articular, and soft tissue injections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Analysis of Implantation of Stromal Vascular Fraction

NCT03226093

Safety Issues

COMPLETED NA

Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes

NCT01453751

Diabetes Mellitus Type II

WITHDRAWN NA

Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia

NCT02099500

Critical Limb Ischemia

WITHDRAWN PHASE1

Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction

NCT01974128

Acute Myocardial Infarction

WITHDRAWN NA

Autologous Bone Marrow Concentrate in Treatment of Erectile Dysfunction.

NCT03699943

Erectile Dysfunction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

SVF Stromal Vascular Fraction is obtained by lipoharvesting, procurement, and lipo-transfer as a same day operative procedure

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurodegenerative Diseases Osteoarthritis Erectile Dysfunction Autoimmune Diseases Cardiomyopathies Emphysema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deployment of stromal vascular fraction

Administration of autologous adipose derived SVF

Group Type EXPERIMENTAL

Administration of autologous adipose derived SVF

Intervention Type PROCEDURE

Intra-venous, intra-articular, and soft tissue injection delivery of SVF

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Administration of autologous adipose derived SVF

Intra-venous, intra-articular, and soft tissue injection delivery of SVF

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must be age 16 or older
* Patient must have a degenerative disease or inflammatory disease that meets criteria for treatment under the IRB which includes: Arthritis, Auto-immune disease,COPD, Cardiomyopathy, Peyronies Disease,Interstitial Cystitis, Erectile Dysfunction, and Neurodegenerative disease such as Parkinsons, ALS, Neuropathy.
* Patient must be healthy enough to tolerate a local anesthetic